[1]王晓洲,吴仰帆,栾晓军.利拉鲁肽对肥胖T2DM患者促炎-抗炎系统及左心舒张功能的影响[J].医学信息,2021,34(22):145-147.[doi:10.3969/j.issn.1006-1959.2021.22.045]
　WANG Xiao-zhou,WU Yang-fan,LUAN Xiao-jun.Effects of Liraglutide on Pro-inflammatory-anti-inflammatory System and Left Ventricular Diastolic Function in Obese T2DM Patients[J].Medical Information,2021,34(22):145-147.[doi:10.3969/j.issn.1006-1959.2021.22.045]
点击复制

利拉鲁肽对肥胖T2DM患者促炎-抗炎系统及左心舒张功能的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年22期
页码:
145-147
栏目:
药物与临床
出版日期:
2021-11-15

文章信息/Info

Title:
Effects of Liraglutide on Pro-inflammatory-anti-inflammatory System and Left Ventricular Diastolic Function in Obese T2DM Patients
文章编号:
1006-1959（2021）22-0145-03
作者:
王晓洲; 吴仰帆; 栾晓军
（佛山市第一人民医院内分泌科，广东 佛山 528000）
Author(s):
WANG Xiao-zhou; WU Yang-fan; LUAN Xiao-jun
(Department of Endocrinology,Foshan First People’s Hospital,Foshan 528000,Guangdong,China)
关键词:
利拉鲁肽; 2型糖尿病; 促炎-抗炎系统; 左心舒张功能
Keywords:
Liraglutide; Type 2 diabetes mellitus; Pro-inflammatory-anti-inflammatory system; Left ventricular diastolic function
分类号:
R587.1
DOI:
10.3969/j.issn.1006-1959.2021.22.045
文献标志码:
A
摘要:
目的 观察利拉鲁肽对肥胖2型糖尿病（T2DM）患者促炎-抗炎系统、左心舒张功能的影响。方法 选择2019年10月-2020年10月我院诊治的40例肥胖T2DM患者作为研究对象，采用随机抽签法分为对照组和观察组，各20例。对照组予以二甲双胍治疗，观察组在对照组基础上联合利拉鲁肽治疗，比较两组血糖指标[空腹血糖（FPG）、糖化血红蛋白（HbA1c）、餐后2h血糖（2hPG）]、促炎因子[白介素-6（IL-6）、高敏-C反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）]、抗炎因子[白介素-4（IL-4）、转化生长因子β1（TGF-β1）]、左心舒张功能指标[二尖瓣环处舒张早期最大运动速度（Em）、舒张早期最大峰值速度/舒张晚期最大峰值速度（E/A）、二尖瓣环处舒张晚期最大运动速度（Am）]及不良反应发生情况。结果 观察组FPG、2hPG、HbA1c低于对照组（P＜0.05）。观察组IL-6、hs-CRP、TNF-α低于对照组，IL-4、TGF-β1高于对照组（P＜0.05）。观察组Em、E/A高于对照组，Am低于对照组（P＜0.05）。观察组不良反应率为20.00%，与对照组10.00%比较，差异无统计学意义（P＞0.05）。结论 利拉鲁肽能可降低肥胖T2DM患者血糖水平，维持促炎-抗炎系统平衡，改善左心舒张功能，且应用安全可靠。
Abstract:
Objective To observe the effect of liraglutide on the pro-inflammatory-anti-inflammatory system and left ventricular diastolic function in obese type 2 diabetes mellitus(T2DM) patients.Methods Forty obese patients with T2DM who were treated in our hospital from October 2019 to October 2020 were selected as subjects. They were randomly divided into control group and observation group, with 20 cases in each group. The control group was treated with metformin, and the observation group was treated with liraglutide on the basis of the control group. The blood glucose indexes [fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), postprandial 2 h blood glucose (2 hPG)], pro-inflammatory factors [interleukin-6 (IL-6), high sensitivity-C reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α)], anti-inflammatory factors [interleukin-4 (IL-4), transforming growth factor-β1 (TGF-β1)], left ventricular diastolic function indexes [maximum early diastolic velocity (Em), maximum early diastolic velocity/maximum late diastolic velocity (E/A), maximum late diastolic velocity (Am) at mitral annulus] and adverse reactions were compared between the two groups.Results The levels of FPG, 2hPG and HbA1c in the observation group were lower than those in the control group(P<0.05). The levels of IL-6, hs-CRP and TNF-α in the observation group were lower than those in the control group, while IL-4 and TGF-β1 were higher than those in the control group(P<0.05). Em and E/A in the observation group were higher than those in the control group, and Am was lower than that in the control group (P<0.05). The adverse reaction rate of the observation group was 20.00%, which was compared with 10.00% of the control group, the difference was not statistically significant (P>0.05).Conclusion Liraglutide can reduce the blood glucose level of obese T2DM patients, maintain the balance of pro-inflammatory and anti-inflammatory system, improve left ventricular diastolic function, and is safe and reliable.

参考文献/References:

[1]曹福建,张翠玲.中西医结合治疗肥胖型2型糖尿病临床研究[J].中医学报,2016,31(11):1688-1690. [2]刘海艳,刘璟琰,何桂香.利拉鲁肽联合二甲双胍治疗肥胖型糖尿病的疗效及微炎症、氧化应激指标观察[J].中国煤炭工业医学杂志,2020,23(2):186-191.[3]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344. [4]史登刚.肥胖与非肥胖2型糖尿病患者左室收缩功能的比较[J].西南国防医药,2016,26(4):376-378.[5]赵炯辉,李俊红,李迎巧,等.利拉鲁肽联合二甲双胍治疗糖尿病合并冠心病患者对血糖、血脂、CRP、心功能的影响[J].疑难病杂志,2017,16(10):989-992,996.[6]周碧芸,叶丽婷.GLP-1类药物利拉鲁肽对自身免疫性糖尿病患者血清炎症因子和抗炎因子水平影响研究[J].检验医学与临床,2016,13(16):2363-2365. [7]谭燚,陆付耳,徐丽君,等.黄连解毒汤对2型糖尿病大鼠细胞因子IL-4和IL-10水平的影响[J].微循环学杂志,2005,15(3):44-45.[8]束芳.多普勒组织成像评价2型糖尿病患者左室舒张功能[J].中国临床医学,2008,15(4):574-575.

相似文献/References:

[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
　HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(22):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
　DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Medical Information,2018,31(22):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的 相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
　CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Medical Information,2018,31(22):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Medical Information,2018,31(22):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[5]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
　LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Medical Information,2018,31(22):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[6]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
　GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2022,35(22):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[7]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
　XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Medical Information,2022,35(22):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[8]余 佳.早期胰岛素强化治疗对初诊2型糖尿病患者血糖控制效果及颈动脉粥样硬化进展的影响[J].医学信息,2022,35(10):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
　YU Jia.Effect of Early Intensive Insulin Therapy on Blood Glucose Control and Progression of Carotid Atherosclerosis in Newly Diagnosed Type 2 Diabetic Mellitus Patients[J].Medical Information,2022,35(22):140.[doi:10.3969/j.issn.1006-1959.2022.10.034]
[9]张剑君.2型糖尿病参与血管衰老的机制[J].医学信息,2022,35(11):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
　ZHANG Jian-jun.The Mechanism of Type 2 Diabetes Mellitus in Vascular Aging[J].Medical Information,2022,35(22):37.[doi:10.3969/j.issn.1006-1959.2022.11.011]
[10]刘 静.利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者 血糖控制及体质量指数的影响[J].医学信息,2018,31(13):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
　LIU Jing.Effect of Liraglutide Combined with Basal Insulin on Blood Glucose Control and Body Mass Index in Newly Diagnosed Type 2 Diabetes Patients with Obesity[J].Medical Information,2018,31(22):137.[doi:10.3969/j.issn.1006-1959.2018.13.040]
[11]曾小兵,朱长东,谢宝强.利拉鲁肽对首诊2型糖尿病患者血糖、血脂及T细胞亚群的影响[J].医学信息,2019,32(22):125.[doi:10.3969/j.issn.1006-1959.2019.22.041]
　ZENG Xiao-bing,ZHU Chang-dong,XIE Bao-qiang.Effect of Liraglutide on Blood Glucose,Blood Lipids and T cell Subsets in Patients with Type 2 Diabetes Mellitus[J].Medical Information,2019,32(22):125.[doi:10.3969/j.issn.1006-1959.2019.22.041]
[12]陶 蕾,张宏江,范中阳.利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的疗效[J].医学信息,2021,34(23):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]
　TAO Lei,ZHANG Hong-jiang,FAN Zhong-yang.Effect of Liraglutide Combined with Insulin in the Treatment of Obesity Type 2 Diabetes Mellitus[J].Medical Information,2021,34(22):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]
[13]张 彤.利拉鲁肽联合胰岛素治疗新诊断肥胖2型糖尿病的临床疗效及安全性[J].医学信息,2022,35(05):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]
　ZHANG Tong.Clinical Efficacy and Safety of Liraglutide Combined with Insulin in the Treatment of Newly Diagnosed Obese Type 2 Diabetes Mellitus[J].Medical Information,2022,35(22):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]
[14]房 芳,于 宏.利拉鲁肽联合二甲双胍治疗2型糖尿病的疗效观察[J].医学信息,2022,35(16):141.[doi:10.3969/j.issn.1006-1959.2022.16.036]
　FANG Fang,YU Hong.Effect of Liraglutide Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus[J].Medical Information,2022,35(22):141.[doi:10.3969/j.issn.1006-1959.2022.16.036]

更新日期/Last Update: 1900-01-01